Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to repurchase A-shares through centralized bidding to enhance investor confidence and maintain shareholder interests [10][11]. Summary by Sections A-share Repurchase Plan - The company intends to repurchase domestic listed RMB ordinary shares (A-shares) [11]. - The repurchased shares will be used for future convertible bond conversions and/or employee stock ownership plans. If not transferred within the legal timeframe, the shares will be canceled within three years [2][17]. - The repurchase price range is set with an upper limit of RMB 30 per share, subject to adjustments in case of dividend distributions or other corporate actions [2][16]. - The total repurchase amount will be no less than RMB 300 million and no more than RMB 600 million [3][14]. - The repurchase period is from January 22, 2025, to July 21, 2025 [3][13]. Funding and Sources - The funding for the repurchase will come from the company's own funds and/or special loans [4][15]. - The company has received a commitment from a bank to provide up to 90% of the repurchase amount as a loan [15]. Management and Shareholder Actions - The company's directors, supervisors, and major shareholders have no plans to sell shares within six months following the board's decision on the repurchase plan [5][20]. - The company will notify the market if any of these parties decide to sell shares during the repurchase period [22]. Impact on Financials and Operations - The repurchase is expected to have a minimal impact on the company's financial condition, with the total repurchase amount representing approximately 0.52% of total assets and 1.27% of net assets as of September 30, 2024 [19]. - The repurchase is not anticipated to affect the company's compliance with listing requirements [19]. Uncertainties and Conditions - The repurchase plan is contingent upon the approval of the 2024 annual general meeting and may be subject to changes based on market conditions or regulatory adjustments [24]. - If the share price exceeds the set range during the repurchase period, the plan may not be fully executed [24]. - The company will follow legal procedures to notify creditors if shares are canceled due to non-transfer [23].
上海复星医药(集团)股份有限公司关于以集中竞价交易方式回购A股的回购报告书